{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:31:54Z","timestamp":1787239914018,"version":"build-2736575974"},"reference-count":48,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtct.2026.05.029","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T06:01:51Z","timestamp":1779429711000},"page":"968.e1-968.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Low SOS\/VOD Risk with Inotuzumab Ozogamicin as a Bridging Strategy to Second Allogeneic HSCT: A Real-World Study in Post-Transplant Relapsed B-ALL"],"prefix":"10.1016","volume":"32","author":[{"given":"Fei","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7964-3181","authenticated-orcid":false,"given":"Jing","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-yu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan-lan","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-jie","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.05.029_bib0001","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s12185-022-03416-7","article-title":"Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment","volume":"116","author":"Kreidieh","year":"2022","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2026.05.029_bib0002","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1182\/blood.2019004043","article-title":"How I treat relapsed acute lymphoblastic leukemia in the pediatric population","volume":"136","author":"Hunger","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.05.029_bib0003","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-136014","article-title":"Significant long-term benefits of CAR T-cell therapy followed by a second allo-HSCT for relapsed\/refractory B-cell acute lymphoblastic leukemia patients who relapsed after an initial transplant","volume":"136","author":"Zhang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.05.029_bib0004","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/bjh.14965","article-title":"Outcome of relapse after allogeneic HSCT in children with all enrolled in the ALL-SCT 2003\/2007 trial","volume":"180","author":"Kuhlen","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2026.05.029_bib0005","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","article-title":"Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.05.029_bib0006","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood-2015-03-633685","article-title":"Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children\u2019s Oncology Group study AALL0232","volume":"126","author":"Borowitz","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.05.029_bib0007","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.3324\/haematol.2018.201053","article-title":"Minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia: a systematic review and meta-analysis","volume":"104","author":"Bassan","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2026.05.029_bib0008","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1200\/JCO.2004.10.050","article-title":"Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial","volume":"22","author":"Thomas","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.05.029_bib0009","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/s41375-024-02318-3","article-title":"How risky is a second allogeneic stem cell transplantation?","volume":"38","author":"Penack","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2026.05.029_bib0010","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/bmt.2015.186","article-title":"Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT","volume":"50","author":"Ruutu","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.05.029_bib0011","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1182\/blood-2024-207504","article-title":"Outcomes of children and young adults with B-cell acute lymphoblastic leukemia given blinatumomab as last consolidation treatment before allogeneic hematopoietic cell transplantation","volume":"144","author":"Algeri","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.05.029_bib0012","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1002\/cncr.32335","article-title":"Transplantation in adults with relapsed or refractory acute lymphoblastic leukemia treated with blinatumomab from a phase 3 study","volume":"125","author":"Jabbour","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2026.05.029_bib0013","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jtct.2026.05.029_bib0014","doi-asserted-by":"crossref","first-page":"e382","DOI":"10.1016\/S2352-3026(23)00064-9","article-title":"Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia","volume":"10","author":"Short","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2026.05.029_bib0015","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.05.029_bib0016","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","article-title":"Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the INO-VATE study","volume":"4","author":"Kantarjian","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2026.05.029_bib0017","series-title":"5th European CAR-T Cell Meeting EHA\/EBMT","article-title":"Inotuzumab ozogamicin as a bridge to allogeneic hematopoietic stem cell transplantation in relapsed pediatric B-cell precursor acute lymphoblastic leukemia after CD19-targeted CAR T-cell therapy","author":"Aertgeerts","year":"2023"},{"key":"10.1016\/j.jtct.2026.05.029_bib0018","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/j.bbmt.2019.04.020","article-title":"Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia","volume":"25","author":"Marks","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.05.029_bib0019","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41409-017-0019-y","article-title":"Management of important adverse events associated with inotuzumab ozogamicin: expert panel review","volume":"53","author":"Kebriaei","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.05.029_bib0020","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/TP.0000000000003569","article-title":"Veno-occlusive disease in HSCT patients: consensus-based recommendations for risk assessment, diagnosis, and management by the GITMO group","volume":"105","author":"Bonifazi","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.jtct.2026.05.029_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1613777","article-title":"Efficacy and safety of inotuzumab ozogamicin and its combination therapies in acute lymphoblastic leukemia: a systematic review and meta-analysis[J]","volume":"15","author":"Lao","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtct.2026.05.029_bib0022","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s11523-025-01129-5","article-title":"CIBMTR registry data on inotuzumab ozogamicin treatment in patients with ALL proceeding to HSCT","volume":"20","author":"de Lima","year":"2025","journal-title":"Target Oncol"},{"key":"10.1016\/j.jtct.2026.05.029_bib0023","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1182\/bloodadvances.2023011514","article-title":"A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia","volume":"8","author":"Metheny","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.05.029_bib0024","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.05.029_bib0025","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.05.029_bib0026","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1038\/s41409-019-0492-6","article-title":"Validation of treatment outcomes according to revised severity criteria from EBMT for sinusoidal obstruction syndrome\/veno-occlusive disease","volume":"54","author":"Yoon","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.05.029_bib0027","first-page":"825","article-title":"1994 Consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.05.029_bib0028","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International multicenter standardization of acute graft-versus-host disease clinical data collection","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.05.029_bib0029","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"NIH consensus criteria for clinical trials in chronic graft-versus-host disease: 2014 diagnosis and staging report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.05.029_bib0030","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/s41409-023-02012-5","article-title":"Long-term outcome of second allogeneic HSCT for primary graft failure in acute leukemia in remission","volume":"58","author":"Nagler","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.05.029_bib0031","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.05.029_bib0032","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1038\/s41467-023-38113-4","article-title":"Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation","volume":"14","author":"Pagliuca","year":"2023","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.029_bib0033","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/bmt.2015.52","article-title":"Sinusoidal obstruction syndrome\/veno-occlusive disease: current situation and perspectives\u2014a position statement from the European Society for Blood and Marrow Transplantation (EBMT)","volume":"50","author":"Mohty","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.029_bib0034","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/bjh.16557","article-title":"Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS\/VOD after haematopoietic cell transplantation","volume":"190","author":"Cairo","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2026.05.029_bib0035","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13045-024-01552-7","article-title":"Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions","volume":"17","author":"Short","year":"2024","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2026.05.029_bib0036","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1182\/blood-2024-200713","article-title":"Inotuzumab ozogamicin administration in first remission results in profound minimal residual disease eradication in adult patients with Ph-negative ALL","volume":"144","author":"Gu","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.05.029_bib0037","doi-asserted-by":"crossref","DOI":"10.1177\/20406207251401046","article-title":"Real-world treatment outcome and toxicity analysis of inotuzumab ozogamicin in relapsed or refractory B-cell precursor ALL","volume":"16","author":"Yoon","year":"2025","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jtct.2026.05.029_bib0038","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1158\/2643-3230.BCD-21-0087","article-title":"Modulation of CD22 protein expression in childhood leukemia by pervasive splicing aberrations","volume":"3","author":"Zheng","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.jtct.2026.05.029_bib0039","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2024023930","article-title":"Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL","volume":"144","author":"Zhao","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.05.029_bib0040","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1182\/blood.2024028215","article-title":"Differentiation-dependent EBF1 activity determines CD22 transcription and leukemia sensitivity to inotuzumab ozogamicin","volume":"146","author":"Escherich","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.05.029_bib0041","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood.2024026085","article-title":"DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia","volume":"145","author":"Escherich","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.05.029_bib0042","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1158\/1078-0432.CCR-11-0486","article-title":"Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin","volume":"17","author":"Ricart","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2026.05.029_bib0043","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/ajh.27254","article-title":"Safety and long-term survival results of the addition of inotuzumab ozogamicin to conditioning for allogeneic stem cell transplantation","volume":"99","author":"Khouri","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2026.05.029_bib0044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-018-0125-6","article-title":"Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant","volume":"8","author":"Fan","year":"2019","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.jtct.2026.05.029_bib0045","first-page":"465","article-title":"Second allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and donor changes in relapsed hematological malignancies after the first transplant","volume":"44","author":"Zhao","year":"2023","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.jtct.2026.05.029_bib0046","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1182\/blood.2023019962","article-title":"Precision medicine approaches to counteract leukemia immune escape after transplant","volume":"143","author":"Tameni","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.05.029_bib0047","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3109\/10428190903586318","article-title":"The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant","volume":"51","author":"Alousi","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2026.05.029_bib0048","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/ejh.13015","article-title":"Outcome following second allogeneic hematopoietic cell transplantation: a single-center experience","volume":"100","author":"Aljasem","year":"2018","journal-title":"Eur J Haematol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726004203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726004203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:35:11Z","timestamp":1785414911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726004203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666636726004203"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.05.029","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low SOS\/VOD Risk with Inotuzumab Ozogamicin as a Bridging Strategy to Second Allogeneic HSCT: A Real-World Study in Post-Transplant Relapsed B-ALL","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.05.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}